<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rebamipide inhibits free radicals derived from activated neutrophils and decreases the inhibiting inflammatory cytokine </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> (BD) is a <z:hpo ids='HP_0011010'>chronic</z:hpo>, multi-systemic <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorder</z:e> with arthritic, gastrointestinal, mucocutaneous, ocular, vascular, and central <z:mp ids='MP_0008912'>nervous</z:mp> system involvement </plain></SENT>
<SENT sid="2" pm="."><plain>This disease has a <z:hpo ids='HP_0011010'>chronic</z:hpo> course with periodic exacerbations and progressive deterioration </plain></SENT>
<SENT sid="3" pm="."><plain>To study the effect of rebamipide treatment to BD-like mice, combination treatment with rebamipide and <z:chebi fb="0" ids="23359">colchicine</z:chebi> was compared to <z:chebi fb="0" ids="23359">colchicine</z:chebi> treatment </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="23359">Colchicine</z:chebi> is one of the most frequently prescribed medicine to the patients with BD </plain></SENT>
<SENT sid="5" pm="."><plain>For each BD mouse, 200 microl gastric fluid or 2 microg <z:chebi fb="0" ids="23359">colchicine</z:chebi> or 150 microg rebamipide or 2 microg <z:chebi fb="0" ids="23359">colchicine</z:chebi> plus 150 microg rebamipide was treated orally once per day </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment was done for 5 consecutive days </plain></SENT>
<SENT sid="7" pm="."><plain>Two hour or 20 days after last administration, spleens were isolated for RT-PCR and real time PCR, and serum was collected for ELISA </plain></SENT>
<SENT sid="8" pm="."><plain>In the combination treated group, TNF alpha, MIP-1 alpha, p22 phox, p47 phox, and gp91 phox <z:chebi fb="2" ids="33699">mRNA</z:chebi> expressions were lower than rebamipide treated or <z:chebi fb="0" ids="23359">colchicine</z:chebi> treated groups by reverse transcriptase PCR </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase subunits <z:chebi fb="2" ids="33699">mRNA</z:chebi> were markedly downregulated compared to the <z:chebi fb="0" ids="23359">colchicine</z:chebi> treated group by real time PCR </plain></SENT>
<SENT sid="10" pm="."><plain>At 20 days after administration, combination treatment decreased 23.5% of the severity score compared to before administration </plain></SENT>
<SENT sid="11" pm="."><plain>In contrast, <z:chebi fb="0" ids="23359">colchicine</z:chebi> treatment decreased 14.3% of the severity score compared to before administration </plain></SENT>
<SENT sid="12" pm="."><plain>Rebamipide helped the function of <z:chebi fb="0" ids="23359">colchicine</z:chebi> to improve the HSV induced BD-like symptoms by inhibiting the expression of <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase in vivo mouse model </plain></SENT>
</text></document>